Current Research

Diabetes Action is committed to funding promising and innovative research to prevent, treat, and cure type 1 and type 2 diabetes and their complications. The following studies are currently being funded by Diabetes Action.

Type 1 diabetes research

A PROGRAM FOR THE CURE OF TYPE 1 DIABETES USING A GENERIC DRUG: PHASE II

Researcher:
Denise L. Faustman, MD, PhD., Associate Professor
Harvard Medical School and Director Immunobiology Laboratory
Massachusetts General Hospital
Charlestown, MA

Purpose:
Dr. Faustman’s group at MGH studies the role of innate and adaptive immunity in the progression and treatment of type 1 diabetes including the potential of the BCG vaccine as a treatment for established type 1 diabetes.  The BCG vaccine is a 125-year-old generic drug originally identified for prevention of tuberculosis, but now clinical trials have shown additional benefits extend to those with type 1 diabetes, autoimmune multiple sclerosis, and in the broad prevention of respiratory infections. In 2018 MGH demonstrated in a Phase I trial that repeat BCG vaccines could lower blood sugars from 10-18% by correcting an underlying defect in metabolism of white blood cells. This benefit was seen even in those who have had type 1 diabetes for decades.  In 2022 and 2024 MGH demonstrated that BCG protects type 1 diabetics from infection and symptoms of COVID-19.  In 2026 results of a 150 patient Phase II double blinded BCG Phase II clinical trial will be published.  Two large pediatric BCG type 1 diabetes trials are currently enrolling.  To date over 500 type 1 diabetics have or are now participating in BCG clinical trials at MGH.

Enhancing Beta-Cell Resilience in Type 1 Diabetes

Researcher:
Stanislovas Jankauskas, PhD
Research Assistant Professor
The CUNY School of Medicine

Purpose:
This study asks a simple question: can a naturally occurring ketone body called beta-hydroxybutyrate (BHB) help protect the insulin-producing beta-cells that are destroyed in type 1 diabetes? In pilot work, a mild BHB-enriched diet delayed diabetes in mice and lowered inflammation in their pancreas. Tests on donated human islets showed that the same ketone eased cellular stress and prevented cell death. Dr. Jankauskas’ lab will now confirm these results and unravel the mechanism behind them, focusing on BHB’s ability to boost “mitophagy,” the cell’s built-in process for clearing damaged mitochondria and keeping energy production healthy. By blending mouse experiments, cutting-edge imaging, and studies of human tissue, this project aims to turn a safe, inexpensive nutritional strategy into a therapy that could prolong beta-cell survival and slow or prevent type 1 diabetes, paving the way for rapid translation to clinical trials.

A novel nanotechnology platform for localized therapies to enhance islet beta-cells replacement and avoid immune rejection 

Researcher:
Diana Velluto, PhD
Research Assistant Professor
University of Miami Miller School of Medicine
Miami, FL

Purpose:
Despite advances, pancreatic islet transplantation is not yet applicable to all the patients because of the need of chronic systemic immunosuppression to prevent rejection. Immunosuppression is unavoidably accompanied by serious side effects including negative effects on transplanted islets. The goal of this research is to address the problem of systemic chronic immunosuppression and extend the applicability of islet transplantation to anyone with type 1 diabetes. Dr. Velluto has developed novel biocompatible and biodegradable nanomedicines, known as Drug-Integrating-Amphiphilic-Nano-Assemblies (DIANAs), useful for many medical needs, including localized immunotherapies that can specifically protect the transplanted islets without damaging other organs. This study aims to demonstrate the ability of these nanomedicines to enhance islet beta-cell transplantation and, finally, to select, among those, the best candidate for clinical use.

Dual-Targeted MSC Exosomes for Localized Immune Tolerance in Type 1 Diabetes

Researcher:
Di Wen, PhD
Assistant Member
Providence Cancer Institute

Purpose:
Type 1 diabetes happens when the immune system mistakenly attacks the insulin-producing cells in the pancreas. Even with modern glucose sensors and insulin pumps, those with type 1 diabetes still face dangerous low blood sugar, unstable glucose levels, and long-term complications. Current immune-suppressing drugs can have serious side effects and often do not last, and islet transplantation is limited by donor shortage and rejection. Dr. Wen’s lab will develop a new, cell-free delivery system using tiny natural particles called exosomes made by mesenchymal stem cells. They will “decorate” these exosomes with two targeting molecules so they home to immune cells (dendritic cells) and the inflamed islet environment, and will load them with calming immune signals (IL-10 or TGF-β) to promote immune tolerance. The lab will then test whether this approach delays diabetes in NOD mice and improves survival and function of transplanted islets.

type 2 diabetes research

Diet-induced diabetes reversed with a nutritional strategy to enhance insulin production and beta cell maturity

Researcher:
Maroof Alam, PhD
Research Investigator
University of Michigan

Purpose:
Among many defects observed in Type 2 diabetes includes increased proinsulin misfolding in pancreatic beta cells. Patients with insulin gene variants that enhance proinsulin misfolding are more susceptible to diabetes, especially with a high-fat diet. Dr. Alam’s lab is studying mice that carry a subtle predisposition to proinsulin misfolding, and develop type 2 diabetes on a high fat diet. The lab will investigate if this high fat diet-induced diabetes can be reversed. They will treat diabetic mice either with a lower-calorie diet or will alternate each day between high-fat eating and fasting (so-called intermittent fasting). Interestingly, both groups will consume the same total calories/week, but the intermittent fasting group reverses their diabetes. This is not caused by increased energy expenditure or by increased insulin sensitivity but instead is caused by increased insulin synthesis in pancreatic beta cells, which raises blood insulin levels to lower blood sugar.

Discovery of free fatty acid carriers in human plasma to advance metabolic health research

Researcher:
Gregory Henderson, PhD
Assistant Professor
Purdue University

Purpose:
In people who are prone to developing type 2 diabetes, the transport of free fatty acids (FFAs) through the bloodstream is elevated. This leads to excessive delivery of fat to sites in the body that normally respond to insulin, ultimately impairing the ability of insulin to control one’s blood sugar. To develop a deeper understanding of type 2 diabetes development, it is necessary to enhance our understanding of FFA transport in blood. While traditionally it was believed that a single protein is responsible for carrying FFAs, it is now apparent from animal research that a broad collection of FFA carriers exists. Dr. Henderson’s lab aims to discover the collection of FFA carriers in humans and will explore how the amount of different FFA carriers in one’s blood relates to one’s health. This work could pave the way for development of therapeutics targeting the transport of FFAs through the bloodstream to treat type 2 diabetes.

A Novel Phytonutrient-Based Combination Therapy for Obesity and Type 2 Diabetes

Researcher:
Dongmin Liu, PhD
Professor
Virginia Tech

Purpose:
The goal of this research is to develop a natural, multi-target approach to prevent and treat obesity and type 2 diabetes (T2D), two closely linked diseases that are increasing rapidly in the United States. Current medications often target only one aspect of these complex conditions, can be expensive, may cause side effects, and lose effectiveness after treatment is stopped. Dr. Liu’s lab has identified elenolic acid, a natural compound found in mature olives, that lowers blood sugar, reduces appetite, and promotes weight loss while preserving muscle mass in animal studies. They will test whether combining this compound with a lower dose of metformin, a commonly used diabetes drug, provides greater benefits than either treatment alone or current GLP-1-based therapies, which are associated with significant muscle loss. The results from this project could lead to a safe, affordable, and more effective therapy for improving long-term health outcomes for people with obesity and T2D.

Defining Why Some Individuals with Diabetes Develop Neuropathy Using Patient-Derived Stem Cell Models

Researcher:
Marisa Medina, PhD
Professor
University of California, San Francisco

Purpose:
Diabetic peripheral neuropathy (DPN) is a common complication of diabetes that causes nerve damage, pain, and loss of sensation, yet we still do not understand why some people develop it while others do not. Dr. Medina’s lab will use stem cells generated from patients to create human nerve cells in the lab and study how they respond to conditions that mimic diabetes, such as high sugar, fat, and inflammation. Their early work shows that nerve cells from people with DPN respond differently to these stresses, suggesting that some individuals may be more inherently vulnerable than others. They will identify the biological pathways that drive this vulnerability and refine a model that better represents the disease. This research will provide critical insight into why DPN develops and lay the groundwork for new strategies to prevent or treat nerve damage in people with diabetes.

Metabolic Profiling and Postprandial Triglyceride Elevation in SLC16A11 Variants

Researcher:
Ankit Shah, MD
Assistant Professor
Rutgers Robert Wood Johnson Medical School

Purpose:
Type 2 diabetes (T2D) affects millions of American adults and leads to long-term complications. Recent studies have shown that mutations, or variants, in the SLC16A 11 gene increase T2D risk, though the underlying mechanism remains unknown. The SLC16A11 gene encodes a protein that transports molecules across the liver, the organ primarily responsible for carbohydrate and fat metabolism. This study will recruit subjects with and without SLC16A11 variants to assess the levels of fat and carbohydrate molecules in their blood (Aim 1). Dr. Shah’s lab will also assess how their bodies make triglycerides, a type of fat, after a standardized meal (Aim 2). They hypothesize that a shift in liver metabolism occurs in subjects carrying the SLC16A 11 gene variant, leading to increased triglyceride (fat) production. By clarifying how the SLC16A11 variant increases the risk of T2D, this research aims to pave the way for targeted, patient-specific therapies to reduce the burden of metabolic disease.

A Patient-Facing mHealth Intervention to Address Gaps in Prediabetes Counseling and Action Planning

Researcher:
Cara Stephenson-Hunter, PhD
Assistant Professor
Albert Einstein College of Medicine

Purpose:
Prediabetes is common and under-treated, yet it represents a critical window for preventing type 2 diabetes that most patients never fully act on. Many patients with prediabetes leave primary care visits without clear information, support, or next steps. Busy clinical visits leave little time for counseling, and patients may not know their prevention options or next steps. This project is developing a smartphone app to help adults with prediabetes understand their risk, evaluate options, and create a personalized prevention plan within routine primary care. The app is grounded in interviews with patients and providers and electronic health record analysis that revealed where the current system falls short. The app will be refined and tested with adults with prediabetes and primary care providers to ensure it is easy to use, acceptable, and practical. This work is the first step toward a larger study testing whether the app helps reduce type 2 diabetes risk.

Recently published research

Researcher:
Julia Matzenbacher dos Santos, PhD
Assistant Professor
University of Pittsburgh
Pittsburgh, PA 

Beyond medication adherence: bisphenol exposure and its relationship with good glycemic control in type 2 diabetes.

dos Santos, J. M., et al. (2026). Beyond medication adherence: bisphenol exposure and its relationship with good glycemic control in type 2 diabetes. Acta Diabetologica. DOI: 10.1007/s00592-026-02794-2.

Researcher:
Dongmin Liu, PhD
Professor
Virginia Polytechnic Institute and State University
Blacksburg, VA 

Olive-derived elenolic acid surpasses metformin and rivals liraglutide in managing blood glucose and obesity in a mouse model of type 2 diabetes

Yao Wang, Hana Alkhalidy, Xinyi Cao, Reagan Vaughan, MD Abu T. Rachi, Bin Xu, Balaji Kale, Abeje Silte, Jennifer Rainville, Georgia E. Hodes, Yan Zhang, Dongmin Liu, “Olive-derived elenolic acid surpasses metformin and rivals liraglutide in managing blood glucose and obesity in a mouse model of type 2 diabetes” The Journal of Nutritional Biochemistry, Volume 150, 2026, https://doi.org/10.1016/j.jnutbio.2025.110206.

Researcher:
Gregory C. Henderson
Assistant Professor
Purdue University
West Lafayette, IN

The Plasma Free Fatty Acid Carrier Proteome is Altered in Diet-Induced and Genetically Obese Mice

K.Tomoo, Y.Zhang, A. Z. D.Portalatin, and G. C.Henderson, “The Plasma Free Fatty Acid Carrier Proteome is Altered in Diet-Induced and Genetically Obese Mice,” Obesity34, no. 6 (2026): 1300–1313, https://doi.org/10.1002/oby.70214.

Researcher:
Prasanth Chelikani, PhD
Professor
Texas Tech University
Amarillo, TX

Maternal Protein Restriction and Branched-Chain Amino Acid Supplementation Differentially Affect Maternal Energy Balance and Impair Offspring Growth

Redrovan D, Patra S, Aziz MT, Gorton MW, Chavez EA, Frederiksen S, Rowe J, Pezeshki A, Chelikani PK. Maternal Protein Restriction and Branched-Chain Amino Acid Supplementation Differentially Affect Maternal Energy Balance and Impair Offspring Growth. Nutrients. 2026 Jan 20;18(2):322. doi: 10.3390/nu18020322.

Prebiotics pectin and resistant starch-type 4 stimulate peptide YY and cholecystokinin to promote satiety, and improve gut microbiota composition

Patra S, Everhart Nunn SL, Levent G, Chelikani PK. Prebiotics pectin and resistant starch-type 4 stimulate peptide YY and cholecystokinin to promote satiety, and improve gut microbiota composition. FASEB J. 2025 Mar 31;39(6):e70457. doi: 10.1096/fj.202403239R. PMID: 40085424.

Microencapsulated Propionate and Butyrate Improved Energy Balance and Gut Microbiota Composition in Diet-Induced Obese Rats 

Patra S, Chelikani PK. Microencapsulated Propionate and Butyrate Improved Energy Balance and Gut Microbiota Composition in Diet-Induced Obese Rats. Nutrients. 2025; 17(13):2180. https://doi.org/10.3390/nu17132180


Researcher:
Vincenza Cifarelli, PhD
Assistant Professor of Pharmacology and Physiology
Saint Louis University School of Medicine
St. Louis, MO

How lipids speak to nerves

V. Cifarelli, How lipids speak to nerves, Proc. Natl. Acad. Sci. U.S.A. 122 (52) e2530035122, https://doi.org/10.1073/pnas.2530035122 (2025).


Researcher:
Bhagirath Chaurasia, PhD
Assistant Professor
University of Iowa
Iowa City, IA

Ceramide signaling in immunity: a molecular perspective

Thakkar, H., Vincent, V. & Chaurasia, B. Ceramide signaling in immunity: a molecular perspective. Lipids Health Dis 24, 225 (2025). https://doi.org/10.1186/s12944-025-02642-2


Researcher:
Liang-Jun Yan, Ph.D.
Professor of Pharmaceutical Sciences
University of North Texas Health Science Center
Fort Worth, TX

Beneficial Effects of Butyrate on Kidney Disease

Diep TN, Liu H, Yan L-J. Beneficial Effects of Butyrate on Kidney Disease. Nutrients. 2025; 17(5):772. https://doi.org/10.3390/nu17050772



Researcher:
Andrew C. Shin, PhD
Assistant Professor
Texas Tech University
Lubbock, TX

BCAAs acutely drive glucose dysregulation and insulin resistance: role of AgRP neurons

 Shah, H., Gannaban, R.B., Haque, Z.F. et al. BCAAs acutely drive glucose dysregulation and insulin resistance: role of AgRP neurons. Nutr. Diabetes 14, 40 (2024). https://doi.org/10.1038/s41387-024-00298-y

Researcher:
Layla Al-Nakkash, Ph.D.
Professor of Physiology
Midwestern University
Glendale, AZ

Deleterious impacts of Western diet on jejunum function and health are reversible

Deleterious impacts of Western diet on jejunum function and health are reversible. Sarah Carpinelli, John Ahlert, Maxwell Rubin, Alex Aratani, Emma Smith, Dana Floyd, Ross M. Potter, and Layla Al-Nakkash American Journal of Physiology-Gastrointestinal and Liver Physiology 2025 328:2, G83-G93 10.1152/ajpgi.00160.2024

Researcher:
EunSeok Cha, Ph.D., MPH, MSN, CDE, RN
Assistant Professor
Emory University Nell Hodson Woodruff School of Nursing
Atlanta, GA

Longitudinal changes in diet quality and food intake before and after diabetes awareness in American adults: the Coronary Artery Risk Development in Young Adults (CARDIA) study

Cha E, Choi Y, Bancks M, Faulkner MS, Dunbar SB, Umpierrez GE, et al. Longitudinal changes in diet quality and food intake before and after diabetes awareness in American adults: the Coronary Artery Risk Development in Young Adults (CARDIA) study. BMJ Open Diabetes Research & Care. 2024;12:e003800. https://doi.org/10.1136/bmjdrc-2023-003800

Researcher:
Gaetano Santulli, MD
Assistant Professor of Medicine
Albert Einstein College of Medicine
Bronx, NY 

A Novel Imaging Marker for Asymptomatic Cerebrovascular Lesions in Hypertension

Gaetano Santulli, Marco Savino, Klara Komici, Pasquale Mone, Luigi Savino, Stanislovas S Jankauskas, A Novel Imaging Marker for Asymptomatic Cerebrovascular Lesions in Hypertension, American Journal of Hypertension, Volume 37, Issue 11, November 2024, Pages 859–860, https://doi.org/10.1093/ajh/hpae100

Researcher:
Li Wen, MD, PhD
Associate Professor in Medicine
Yale University School of Medicine
New Haven, CT 

Tlr9 deficiency in B cells leads to obesity by promoting inflammation and gut dysbiosis

Pai Wang, Xin Yang, Luyao Zhang, Sha Sha, Juan Huang, Jian Peng, Jianlei Gu, James Alexander Pearson, Youjia Hu, Hongyu Zhao, F. Susan Wong, Quan Wang & Li Wen, Tlr9 deficiency in B cells leads to obesity by promoting inflammation and gut dysbiosis, Nature Communications, volume 15, Article number: 4232 (2024) https://doi.org/10.1038/s41467-024-48611-8

Researcher:
Douglas Sobel, MD
Professor of Pediatrics, Chief Pediatric Endocrinology
Georgetown University
Washington, DC

Preparation of PLGA Microspheres Using the Non-Toxic Glycofurol as Polymer Solvent by a Modified Phase Inversion Methodology

Sobel D, Ramasubramanian B, Sawhney P, Parmar K. Preparation of PLGA Microspheres Using the Non-Toxic Glycofurol as Polymer Solvent by a Modified Phase Inversion Methodology. Polymers. 2024; 16(3):434. https://doi.org/10.3390/polym16030434